先聲藥業(02096.HK)抗新冠藥先諾欣研究顯示可加快症狀恢復

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)抗新冠藥先諾欣研究顯示可加快症狀恢復

阿思達克 01-19 00:41

先聲藥業(02096.HK)公佈，《新英格蘭醫學雜誌》發表集團抗新冠創新藥先諾欣治療輕中度COVID-19成年患者II/III期臨牀研究結果。結果顯示，對內地輕中度COVID-19成年患者，先諾欣可加快症狀恢復，縮短病程，快速、大幅降低病毒載量，且安全耐受性良好。該研究中納入患者年齡中位數爲35歲，1,092例(95.9%)患者已完成首次疫苗接種，其中874例(76.7%)患者接受過加強劑量。

先声药业(02096.HK)

Relevant Stocks

先声药业(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)抗新冠藥先諾欣研究顯示可加快症狀恢復

Services

About Us

Agreement Statement